1 / 9

Prader Willi Syndrome Market Share

DelveInsight's "Prader-Willi Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<br><br>

yashb
Download Presentation

Prader Willi Syndrome Market Share

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What is PraderWilli Syndrome Market Share? By DelveInsight Business Research

  2. About PraderWilli Syndrome Market Share Intranasal carbetocin is similar to the naturally-occurring hormone oxytocin, but with greater selectivity for the effect of interest stimulation of oxytocin receptors. These receptors are involved in the regulation of both social-emotional and feeding behaviors

  3. It is approved in over 90 countries outside the United States for the prevention of uterine atony and excessive bleeding during cesarean section delivery. In a press release, Levo Therapeutics stated that the phase 3 study achieved statistical significance with the secondary endpoint evaluating the 3.2 mg dose

  4. However, the study did not meet its primary endpoint evaluating the 9.6 mg dose of LV-101. Enrollment for the study was closed early due to COVID-19, with 119 evaluable patients in the primary analysis set.

  5. Harmony Biosciences intends to commence Phase 2 clinical trial, which was postponed April due to COVID-19, to evaluate pitolisant for the treatment of EDS and other vital symptoms in patients with PWS in the second half of 2020, with topline results expected in the first half of 2022.

  6. Pitolisant enhances the activity of histaminergic neurons, a type of nerve cell that helps fight uncontrollable sleepiness or narcolepsy. It works by blocking the histamine 3 (H3) receptor, increasing the production and release of histamine, a neurotransmitter that regulates the sleep-wake system, and promotes wakefulness.

  7. The therapy was approved by the US Food and Drug Administration in August 2019, under the brand name Wakix, to treat excessive daytime sleepiness in adults with narcolepsy. Read More@PraderWilli Syndrome Market Size

  8. Thank You

More Related